Department of Ophthalmology, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China (mainland).
Department of Ophthalmology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China (mainland).
Med Sci Monit. 2024 May 7;30:e943240. doi: 10.12659/MSM.943240.
Behçet uveitis poses significant management challenges, owing to its intricate pathogenesis and the severe prognosis it harbors, frequently culminating in irreversible visual impairment and an elevated risk of blindness. This review synthesizes contemporary insights into personalized immunosuppressive strategies for Behçet uveitis, emphasizing the necessity for a customized approach in recognition of the disease's heterogeneity and the variable responsiveness to treatment. This discourse elaborates on the application, efficacy, and safety profiles of traditional immunosuppressants, highlighting a paradigm shift toward integrative combination therapies aimed at diminishing reliance on glucocorticoids and mitigating their associated adverse effects. This thorough evaluation seeks to enlighten clinical practices and spearhead future investigations aimed at refining the management of Behçet uveitis, championing a personalized, multidisciplinary strategy to amplify therapeutic efficacy and enhance patient quality of life.
贝赫切特葡萄膜炎的发病机制复杂,预后严重,给临床管理带来了巨大挑战,常导致不可逆的视力损害和较高的失明风险。本综述综合了当前关于贝赫切特葡萄膜炎个体化免疫抑制策略的研究进展,强调了在认识到疾病异质性和治疗反应性差异的基础上,采用个体化治疗方法的必要性。本文详细阐述了传统免疫抑制剂的应用、疗效和安全性特征,并探讨了向综合联合治疗方案转变的必要性,以减少对糖皮质激素的依赖并减轻其相关不良反应。本文旨在为临床实践提供指导,并为进一步的研究提供参考,以优化贝赫切特葡萄膜炎的管理,倡导个体化、多学科的治疗策略,提高治疗效果,改善患者的生活质量。